Russian scientists have performed trials of an innovative treating agent, which brings new hopes to curing hemophilia.
      
      First international blind clinical trial of a brand new technique for preventive replacement therapy of hemophilia has been performed in several Russian clinics (Centre of Hemophilia, Republican Centre and Reconstruction and Recovery Surgery Department). Trial results were published in “Blood” magazine.
      
      It was the first time the trial was performed on patients, however preliminary conclusions of medical experts were confirmed – periods without bleeding became longer, which is crucial for patients with severe hemophilia.
      
      The innovation drug (Kogenate) is produced by Bayer AG pharmaceutical company.
      
      Source: Commercial Biotechnology